Nathan Sadeghi-Nejad

Nathan Sadeghi-Nejad has 15 years experience as a professional health-care investor, most recently as a sector head for Highside Capital. He has worked on the sell side (with independent research boutiques Sturza¿s Medical Research and Avalon Research) and the buyside (at Kilkenny Capital prior to Highside). Sadeghi-Nejad is a graduate of Columbia University and lives in New York. You can follow him on Twitter @natesadeghi.

Recent Articles By The Author

Making The Call: Celgene's Abraxane Will Work in Pancreatic Cancer

Making The Call: Celgene's Abraxane Will Work in Pancreatic Cancer

A key question is whether Abraxane will be used more than a cheaper, four-drug chemo cocktail.

Sarepta Shares Still Have Upside

Sarepta Shares Still Have Upside

Contributor Nate Sadeghi works the numbers and says Sarepta is still under-valued.

Threshold's Pancreatic Cancer Drug May be Obsolete Before Launch

Threshold's Pancreatic Cancer Drug May be Obsolete Before Launch

Improved treatments for pancreatic cancer challenge the relevance of Threshold's TH-302

A New Reason to be Bullish About Sarepta Therapeutics

A New Reason to be Bullish About Sarepta Therapeutics

A longer study blind suggests eteplirsen is really helping muscular dystrophy patients.

Idenix Pharma: Guilty By Association

Idenix Pharma: Guilty By Association

Idenix shares are dead money due to FDA safety concerns about Idenix's lead hepatitis C drug.

Bull Case on Peregrine Pharma Shouldn't Be Dismissed

Bull Case on Peregrine Pharma Shouldn't Be Dismissed

Believers in Peregrine's lung cancer drug bavituximab state their case.

Peregrine Pharma: Not Good Enough to Own, Too Risky to Short

Peregrine Pharma: Not Good Enough to Own, Too Risky to Short

Nate Sadeghi examines Peregrine's lung cancer drug bavituximab

More Reasons to Invest in Sarepta With Caution

More Reasons to Invest in Sarepta With Caution

Nate Sadeghi answers critics who think he's being too hard on Sarepta and its DMD drug eteplirsen.

Sarepta's Risks Shouldn't Be Ignored

Sarepta's Risks Shouldn't Be Ignored

There are legit reasons to like Sarepta Therapeutics but only if these red flags can be avoided.

In These Turbulent Times, Reach for Merck

In These Turbulent Times, Reach for Merck

The company's pipeline could deliver an upside surprise, plus you get a 4% dividend while you wait.